🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — July 23, 2026

This executive compensation digest reveals a bifurcated landscape across the 13 filings. On one side, high-performance companies like Logitech and Transcat are rewarding executives with above-target bonuses and record PSU vesting, signaling strong operational momentum and management confidence. Conversely, several micro-cap and special situation filings, including VisionWave Holdings and CalciMedica, present complex governance proposals with heavy equity dilution, insider-driven transactions, and potential for significant shareholder value transfer. A notable theme is the prevalence of reverse stock split proposals (CalciMedica, VisionWave) and M&A-related compensation (First Seacoast, Forum Funds), which create both risks and opportunities for investors. The lack of insider selling or buying in most filings, combined with the high number of routine 'Say on Pay' votes, suggests a generally stable but cautious executive compensation environment, with the most actionable signals coming from the few companies with strong financial performance and clear forward-looking guidance.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 23, 2026

The IPO pipeline for July 23, 2026, reveals a bifurcated market: one traditional operating company (Syntec Optics) is attempting to go public after resolving severe compliance issues, while two others (Innovative Eyewear and Lyntris) are burdened by weak financial health and governance red flags. AParadise Acquisition Corp. represents the SPAC sector, but its small size and forfeiture of founder shares signal muted sponsor confidence. No period-over-period revenue or margin trends are available across these pre-revenue or pre-IPO entities, but the absence of insider buying and the presence of material weaknesses in internal controls (Lyntris) and out-of-the-money warrants (Innovative Eyewear) suggest cautious investor sentiment. The most critical development is Lyntris's $284.7M debt load and unremediated control weaknesses, which could deter institutional participation. Overall, the pipeline lacks high-quality, growth-stage issuers, indicating a potential lull in new listings.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 23, 2026

On July 22-23, 2026, five US-listed small-cap and micro-cap companies disclosed regulatory listing challenges, highlighting a concentrated round of Nasdaq compliance failures. The filings reveal two distinct themes: immediate trading suspensions/delistings (Nuvve Holding Corp.) and grace-period remediation efforts (Aprea Therapeutics, Fly-E Group, InspireMD, Shore Bancshares). A critical portfolio-level trend is the prevalence of non-compliance with the $1.00 minimum bid price rule (3 of 5 companies), alongside periodic reporting failures (2 of 5). No insider trading activity was reported by any of the companies, suggesting management may be limited in their ability to signal confidence amid regulatory uncertainty. Forward-looking data shows key catalyst dates through January 2027, creating a defined timeline for potential reversals or further downside. The most material development is Nuvve's imminent suspension and move to OTC Pink, representing a near-certain loss of exchange liquidity. The sector-wide pattern suggests increasing regulatory scrutiny on micro-cap compliance with Nasdaq's quantitative and procedural standards.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — July 23, 2026

This digest covers 35 filings focused on executive and director changes, with a notable concentration of CFO transitions and board appointments. The most significant development is the CFO departure at GE HealthCare, a high-materiality event (8/10) accompanied by strong preliminary Q2 results (revenue +5.7% YoY, organic +3.5%) and reaffirmed guidance, creating a mixed signal. A wave of planned retirements and successions is evident, including the CEO of Popular, Inc., the CFO of Albertsons, and the founder-CEO of Mobileye, signaling a period of leadership renewal across sectors. Several companies are using compensation actions to retain key talent, such as Franklin Resources' $15M retention awards and Arq's restructured CEO agreement with aggressive stock price targets. The data reveals a bifurcated market: established firms like GE HealthCare and ADM are strengthening their benches with experienced operators, while smaller companies like Allurion and Cingulate face leadership vacuums or role eliminations. Insider activity is limited to compensation-driven grants, with no open-market buying or selling detected, suggesting management is focused on alignment rather than signaling conviction. The overall tone is neutral, with pockets of positive sentiment from strategic appointments and negative sentiment from sudden departures.

35 high priority 35 total filings
· daily

USA Insider Trading Pulse — July 23, 2026

The July 23, 2026 insider trading pulse reveals a bifurcated market: aggressive insider buying at beaten-down small-caps (Byrna Technologies, 51Talk, Energizer Holdings) contrasts with significant, high-value sales at large-cap leaders (Travelers, Credo Technology, Cytokinetics). The most notable cluster is the coordinated, large-scale option grant to six directors at Perma-Fix Environmental Services, signaling a strategic board-level refresh. Period-over-period comparisons from the enriched data show that insider sentiment is most positive in the environmental services and online education sectors, while the insurance and semiconductor supply-chain spaces show bearish conviction from top executives. A key pattern is the use of Rule 10b5-1 plans for sales at Travelers and Credo, suggesting pre-planned diversification rather than reactive fear, but the sheer dollar volume ($7.45M combined at Travelers) demands attention. The data also reveals a capital allocation theme of stock-for-tax withholding at MillerKnoll and Sun Communities, which is a neutral signal but indicates high equity compensation levels. Overall, the stream points to a 'risk-on' rotation by corporate insiders into undervalued growth stories, while insiders at high-flying names are taking profits.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 23, 2026

The July 23, 2026 filings reveal a bifurcated US M&A landscape: SPAC activity remains robust with two new IPOs (B&R Technology Merger Corp. raising $325M and Southern Cross Acquisition I Corp. raising $100M) and three SPACs extending deadlines (Cayson, Four Leaf, and Bleichroeder's Pasqal deal progressing), signaling sustained appetite for blank-check vehicles despite market volatility. However, the most actionable intelligence comes from operating companies: Gentherm posted record revenue ($416.2M, +11% YoY) but experienced margin compression (-70 bps) and a dramatic cash flow decline (from $31.7M to $2.3M), while raising guidance and announcing a $400M buyback—a mixed signal. Tharimmune's divestiture of Gravitas Life Sciences for a $3.5M promissory note improves its loss profile (pro forma net loss improving from -$35.9M to -$25.8M for FY2025) but leaves it with a $113.7M deferred tax liability and ongoing digital asset losses. XMax's indirect investment in Figure AI via a fund structure (48% interest for $8M) represents a novel SPV approach to accessing high-growth private AI. Portfolio-level trends show SPACs dominating volume (6 of 10 filings) but operating companies providing the most material financial insights, with period-over-period comparisons highlighting revenue growth offset by margin and cash flow deterioration.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 23, 2026

Overnight filings reveal a market bifurcated between strong operational performance and rising strategic uncertainty. Columbia Financial Inc. saw an extraordinary wave of insider buying, with 12 executives and directors collectively purchasing over $3.3 million of stock at $10.00 per share, signaling profound conviction in a deeply undervalued asset. Conversely, a high-stakes governance battle is unfolding at Hilltop Holdings, where the largest shareholder (26.7% stake) is voting against all directors and executive compensation, creating significant headline risk. On the earnings front, Alphabet and Thermo Fisher delivered standout results, with revenue surging 24% and 10% respectively, though Alphabet's massive net income jump was driven by non-operating items. Tesla's Q2 showed a worrying divergence: revenue grew 25.5% YoY, but operating income collapsed 56.9% due to soaring expenses, and regulatory credit revenue plunged 67%. Comcast's mixed report highlighted a strategic pivot, with a share repurchase pause and record wireless additions, but continued broadband losses. A key portfolio-level trend is the divergence in capital allocation: while Allegion aggressively bought back shares (+101% YoY), Comcast paused its program, signaling different stages of corporate lifecycle and strategic transformation.

35 high priority 15 medium 50 total filings
· daily

New Federal Contractors — July 22, 2026

This digest covers two defense-related contracts totaling $278.5 million, with a 100% defense/civilian split (both are defense-related). The dominant theme is a mix of legacy NASA mission assurance work and a current FDA public health communications campaign, indicating no single sector concentration. The highest-conviction signal is the $95.8 million TRUE NORTH COMMUNICATIONS INC award from the FDA, which provides multi-year revenue visibility through December 2026 but carries execution risk tied to civilian agency appropriations. A key watch item is the lack of recent contract wins for ARES TECHNICAL SERVICES CORPORATION, whose $182.7 million NASA contract ended in 2019, limiting forward revenue visibility.

2 total filings
· daily

Significant Contract Modifications ($10M+) — July 22, 2026

The two contracts analyzed, totaling $278.5 million, are both defense-related in the context of government services but split between a legacy NASA award and a current civilian HHS/FDA campaign. The dominant signal is neutral, with an average strength of 4.5/10, as the largest award ($182.7M to Ares Technical Services) is a completed contract from 2012-2019 offering no forward revenue visibility. The highest-conviction signal is the $95.8M True North Communications FDA contract, which provides a multi-year revenue stream through 2026 but is in a non-defense, service-oriented sector with capped margins. A key risk is the lack of recent competitive wins for Ares Technical Services, suggesting potential revenue gaps, while the True North contract faces execution risk tied to annual appropriations for civilian public health campaigns.

2 total filings
· daily

Contract Deobligations Alert — July 22, 2026

This digest covers $278.5 million in total obligations across two defense-related contracts, both neutral in signal. The largest award is a $182.7 million cost-plus-fixed-fee contract from NASA to Ares Technical Services Corporation, but it ended in 2019, offering no current revenue visibility. The second is a $95.8 million time-and-materials delivery order from the FDA to True North Communications Inc for a national education campaign, providing multi-year revenue through December 2026. The highest-conviction signal is the True North contract, which is a competitive win under full-and-open competition, but its civilian agency (HHS/FDA) exposure subjects it to annual appropriations risk. Key watch item: monitor FDA budget allocations for public health campaigns and any contract modifications for True North.

2 total filings
· daily

Contract Option Exercises — July 22, 2026

The two contract option exercises totaling $278.5 million are both defense-related, but they reveal a bifurcated investment story: a legacy, fully-obligated NASA cost-plus contract with Ares Technical Services ($182.7M) offers no forward revenue visibility, while a newer, active FDA communications campaign contract with True North Communications ($95.8M) provides a multi-year civilian revenue stream through December 2026. The highest-conviction signal is the neutral-to-slightly-bullish True North award, which demonstrates competitive win capability in a full-and-open civilian market, though capped by time-and-materials pricing. A key risk is the Ares contract's completion in 2019, which leaves current revenue streams unverified and creates a concentration risk if the company lacks follow-on awards. The aggregate signal strength is low (4.5/10), reflecting limited actionable forward-looking data for investors.

2 total filings
· daily

All HHS Contracts — July 22, 2026

This digest covers a single $95.8 million civilian contract awarded to TRUE NORTH COMMUNICATIONS INC by the FDA (HHS) for a national education campaign, with $33 million already outlaid. The contract is time-and-materials, limiting margin upside but reducing execution risk, and runs through December 2026. As the sole contract in the period, it represents a pure civilian agency win with no defense exposure, signaling stable but non-cyclical revenue tied to public health appropriations. The highest-conviction signal is neutral, reflecting a competitive win with capped profitability and multi-year visibility. Key risks include annual appropriations uncertainty for HHS public health campaigns and potential execution delays tied to campaign performance metrics.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 22, 2026

The two contracts analyzed total $278.5M in obligations, both defense-related but spanning distinct agencies: NASA ($182.7M) and HHS/FDA ($95.8M). The NASA contract with Ares Technical Services is a completed award (2012-2019), offering no forward revenue visibility, while the FDA contract with True North Communications provides a multi-year stream through 2026. The highest-conviction signal is the neutral-to-bullish FDA award, given its recent date and competitive win, but execution risk tied to civilian appropriations and time-and-materials pricing caps upside. Key risk: the NASA contract's completion leaves Ares Technical Services without current revenue from this source, requiring monitoring for new awards.

2 total filings
· daily

General Federal Contracts — July 22, 2026

This digest covers two defense-related contracts totaling $278.5 million, split between a legacy NASA award to Ares Technical Services Corporation ($182.7M, completed in 2019) and an active FDA campaign contract to True North Communications Inc ($95.8M, through 2026). The dominant theme is a lack of forward-looking revenue visibility: the largest contract is historical, while the active contract is a civilian agency time-and-materials award with capped margins. The highest-conviction signal is the True North Communications win, which provides a multi-year revenue stream but is tied to non-defense appropriations. Key risks include the absence of recent defense prime awards and execution risk tied to FDA budget cycles.

2 total filings
· daily

All NASA Contracts — July 22, 2026

This digest covers a single NASA contract worth $182.7M awarded to Ares Technical Services Corporation, a small business, for safety and mission assurance services at Goddard Space Flight Center. The contract is fully obligated and completed (ended November 2019), offering no forward-looking revenue visibility. As the sole award in the period, it is classified as defense-related but carries a neutral signal with low materiality (3/10). Key risks include the contract's age and lack of current revenue generation, while the small business set-aside and cost-plus pricing structure provide historical context for Ares Technical's competitive positioning. Investors should monitor for new awards to assess current revenue streams and competitive moat.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 22, 2026

The six S&P 500 Technology filings for July 22, 2026, reveal a sector bifurcated between strong top-line growth and rising investment costs. ServiceNow, Texas Instruments, and IBM all posted double-digit YoY revenue gains (22%, 23%, and 12% respectively), driven by AI and cloud demand, but each reported margin compression from increased AI R&D and infrastructure spending. This pattern suggests a sector-wide 'show me the ROI' moment for AI investments. Concurrently, insider selling at Datadog, Arista Networks, and CrowdStrike—all under Rule 10b5-1 plans—signals that top executives are systematically cashing out at current valuations, adding a layer of caution. The key portfolio-level takeaway is that while AI tailwinds are real and driving growth, the associated cost pressures and insider activity warrant a selective, quality-focused approach. Texas Instruments stands out with a 271% surge in free cash flow and a strong Q3 guidance raise, positioning it as a relative outperformer in capital efficiency.

3 high priority 3 medium 6 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 22, 2026

The 9 filings from NASDAQ-100 constituents reveal a stark divergence in the AI era: mega-cap leaders like Alphabet and Texas Instruments are posting exceptional revenue and profit growth (Alphabet's Cloud revenue surging 82% YoY, TI's Analog segment up 26% YoY), while Tesla's core auto margins are compressing despite 26% revenue growth. A clear pattern of massive capital allocation toward AI infrastructure emerges, with Alphabet's assets nearly doubling to $922B and Tesla's capex surging 142% YoY to $5.8B. Insider activity is notably bearish at CoreWeave, where the Chief Development Officer sold nearly $7M in stock across multiple filings, reducing his stake to near zero. Meanwhile, Meta's COO executed a routine 10b5-1 plan sale. Netflix's $1B debt refinancing at 5.250% is a neutral capital management move. The overarching theme is that AI-driven growth is creating winners and losers even within the same index, with profitability and free cash flow generation becoming key differentiators.

8 high priority 1 medium 9 total filings